Table 2.
Clinical characteristics and metabolic profiling of non-MASLD, MASLD and MASH patients.
| Non-MASLD (n = 24) | MASLD (n = 14) | MASH (n = 3) | p-value | |
|---|---|---|---|---|
| Age | 49.7 ± 13.5 | 45.08 ± 13.1 | 56.33 ± 7.5 | 0.37 |
| Sex (F) | 19 | 10 | 3 | 0.72 |
| Ethnicity | 0.043 | |||
| Asian/British Asian | 2 | 0 | 1 | |
| Black/black Caribbean | 6 | 1 | 0 | |
| White | 14 | 8 | 1 | |
| Other | 0 | 4 | 1 | |
| Mixed | 2 | 1 | 0 | |
| BMI (m2/kg) | 45.89 ± 6.7 | 46.68 ± 11.7 | 46.68 ± 11.7 | 0.96 |
| HbA1C (mmol/moll) | 40.33 ± 6.1 | 42.36 ± 12.11 | 57.33 ± 24.21 | 0.24 |
| Cholesterol (mg/dL) | 4.5 ± 1.3 | 4.8 ± 0.99 | 4.57 ± 1.09 | 0.73 |
| Triglyceride (mg/dL) | 1.2 ± 0.68 | 1.8 ± 2.4 | 2.07 ± 1.77 | 0.31 |
| Medicines | ||||
| Metformin | 3 (12.5%) | 4 (29%) | 1 (33%) | 0.36 |
| Gliclazide | 0 (0%) | 1 (7%) | 1 (33%) | 0.05 |
| Empagliflozin | 0 (0%) | 1 (7%) | 1 (33%) | 0.05 |
| Sitagliptin | 0 (0%) | 0 (0%) | 0 (0%) | |
| Liraglutide | 0 (0%) | 1 (7%) | 0 (0%) | 0.40 |
| Statin | 5 (36%) | 3 (21.4%) | 1 (33%) | 0.86 |
| ACE-i/ARB | 11 (46%) | 4 (28%) | 2 (66%) | 0.45 |
| Aspirin | 2 (8%) | 1 (7%) | 0 (0%) | 0.99 |
| Co-morbidities | ||||
| Hypertension | 11 (46%) | 7 (50%) | 2 (66%) | 0.89 |
| Dyslipidaemia | 3 (12.5%) | 3 (21.4%) | 1 (33%) | 0.53 |
| Ischaemic heart disease | 1 (4.2%) | 0 (0%) | 0 (0%) | 0.99 |
| MASLD/MASH | 0 (0%) | 14 (100%) | 3 (100%) | <0.0001 |
Statistical significance calculated using Kruskal–Wallis test or Fisher's exact test. Non-MASLD: non-Metabolic dysfunction-associated steatotic liver disease; MASLD: Metabolic dysfunction-associated steatotic liver disease; MASH: Metabolic dysfunction-associated steatohepatitis; BMI: body mass index; HbA1C: glycated haemoglobin; ACE-i: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker.